

## SHORT CURRICULUM VITAE

**Name:** David Baker  
**Title:** Professor of Neuroimmunology

### Education

Bedford College, University of London BSc (Zoology) 1983  
Hunterian Institute, University of London PhD (Immunology)  
1987

### Employment History:

QMUL London	Professor	2006-present
UCL Institute of Neurology	Professor	2004-2006
UCL Institute of Neurology	Senior Lecturer	1999-2004
UCL Institute of Ophthalmology,	Principal Research Fellow/Senior Lecturer	1994-2000
Hunterian Institute London,	Lecturer	1988-1994
Institute of Basic Medical Sciences	Research Assistant	1983-1988

### Commercial History:

Founder Canbex Therapeutics 2005-present

### RECENT PUBLICATIONS

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. (2017) Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. *EBioMedicine*; 16: 41-50

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. *JAMA Neurol*. 17: 961-969

Baker D, Herrod SS, Alvarez-Gonzalez, Zalewski L, Albor C, Schmierer K. (2017) Both cladribine and alemtuzumab may affect MS via B cell depletion. *Neurol Neuroinflamm Neuroimmunol* 4; e360.

Baker D, Pryce G, Visintin C, Sisay S, Bondarenko AI, Ho WSV, Jackson SJ, Williams TE, Al-Izki S, Sevastou I, Graier WF, Stevenson L, Tanner C, Ross R, Pertwee RG, Henstridge CM, Irving AJ, Schulman J, Powell K, Ravic M, Baker MD, Giovannoni G, Selwood DL. (2017) Big conductance calcium-activated potassium channel openers control spasticity without sedation. *Brit J Pharm*. 174:2662-2681

Giovannoni G, Cutter G, Pia-Sormani M, Leppert D, Belachew S, Knappertz V, Tomic D, Herndon R, Carassiti D, Baker D, Schmierer. (2017) Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. *Mult Scler Rel Dis*. 12; 70-78

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K. (2018) Alemtuzumab depletion failure can occur in multiple sclerosis. *Immunology*. 154:253-260.

Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K. (2017) Disease modification in advanced MS: Focus on upper limb function. *Mult Scler J*. 23: 1956-1957.

Puentes F, van der Star BJ, Lidster, K, Boomkamp S, Kipp Markus, Boon L, Bosca, I, Raffel J, Gnanapavan S, van der Valk P, Stephenson J, Barnett S, Baker D, Amor S. (2017) Neurofilament light as an immune target for pathogenic antibodies. *Immunology*. 152:580-588.

Sefia E, Pryce G, Meier UC, Giovannoni G, Baker D. (2017) Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. *Mult scler rel dis*. 2017. 14:46-50.

Dubuisson N, Bauer A, Buckley M, Paterson A, Gilbert R, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Klaus S, Thomson A. (2017) Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. *Mult Scler Rel Dis* 17:172-176.

Baker D, Giovannoni G, Schmierer K. (2017) Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. *Mult Scler Relat Disord*. 18:181-183.

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D, Gnanapavan S, Schmierer K. (2018) Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. *Mult Scler Relat Disord*. 24: 20-27.

Alvarez-Gonzalez C, Adams A, Turner BP, Giovannoni G, Baker D, Schmierer K. (2017) Cladribine to treat disease exacerbation in progressive multiple sclerosis. *Annal clinical trans neurol*. 17: 506-511

von Kutzleben S, Pryce G, Giovannoni G, Baker D. (2017) Depletion of CD52 inhibits central nervous system autoimmunity but blocks tolerance induction: Implications for secondary of alemtuzumab in multiple sclerosis. *Immunol*. 150:444-455

Thomson A, Raciborsk D, Baker D, Giovannoni G. (2017) How to start a blog. *Pract Neurol* . 17:224-228.

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K. (2018) Axonal loss in the multiple sclerosis spinal cord revisited. *Brain Pathol*. 28: 334-348.

Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ, Giovannoni G, Schmierer K. (2018) Cladribine may inhibit multiple sclerosis via depletion of memory B cells. *J Neurol* 265:1199-1209.

Afolabi D, Albor C, I. Zalewski, Baker D, Schmierer K. (2018) Positive impact of cladribine on the quality of life in people with relapsing multiple sclerosis. *Mult Scler J*. doi: 10.1177/1352458517726380. [Epub]

Mao Z, Alvarez-Gonzalez C, Albor C, Doctor G, Soon D, Pepper G, Turner BP, Marta M, Mathews J, Giovannoni G, Baker D, Schmierer K (2018). Cladribine: off-label disease modification for people with multiple sclerosis in resource poor settings? *Mult Scler J: Exp Trans clin*. DOI: 10.1177/ 2055217318783767 [Epub]

Bo X, Gushina S, Pryce G, Yip P, Wu D, Pallier P, Giovannoni G, Baker D. (2018). Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. *Glia* in press

Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. (2018). *J Neurol, Neurosur, Psych*. In press.

Pryce G, Baker D. (2018) Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? *Mult Scler Relat Disord*. In press.